-
A peatland in the Amazon stopped absorbing carbon. What does it mean?Peatlands cover just a fraction of Earth's surface, but store huge amounts of carbon. In the Peruvian Amazon, one of these swamps has switched to carbon neutral.
-
We're within 3 years of reaching a critical climate threshold. Can we reverse course?A report published in June found that the world only has three years before it crosses the 1.5 C climate target. So what should we do now?
-
8 babies spared from potentially deadly inherited diseases through new IVF 'mitochondrial donation' trialA groundbreaking trial in the U.K. has released data on eight babies born through a special IVF procedure to lower their risk of mitochondrial DNA disease.
-
How is DNA used to identify victims of mass disasters?DNA analysis is considered the gold standard for identifying victims of mass fatalities. But how does it work?
-
Astronomers are racing to study our solar system's newest 'interstellar visitor.' Here's why.Astronomers have been given the rare opportunity to study an extrasolar object after the recent discovery of the interstellar comet 3I/ATLAS. Experts tell Live Science how they are planning to observe the cosmic visitor.
-
Antarctic sea ice collapse linked to a mysterious spike in ocean saltSatellite imagery has revealed a yet-to-be-explained rise in the Southern Ocean's salinity. It could be a key factor in the decline of the region's sea ice.
-
A dangerous condition that can cause seizures, coma and death could rise dramatically as the climate warmsResearchers are uncovering a link between rising temperatures and hyponatremia, a condition caused by a dangerous decline in sodium in the body.
5 Comments -
8-year-old with rare, fatal disease shows dramatic improvement on experimental treatmentA child with a rare genetic disease that affects mitochondria is the first person to receive a new experimental treatment for the potentially life-threatening condition.
8 Comments -
Ozempic-style drugs treat type 1 diabetes, not only type 2, study findsA clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with type 1 diabetes.
